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Very few data exist on when a particular thrombopoietin-receptor agonist (tpo-RA) is favored in clinical 
practice for the treatment of patients with immune thrombocytopenia (itp), about novel risk factors 
for vascular events (Ve) with these drugs, nor about predictive factors for therapy free responses (tfR). 
We conducted an observational, retrospective, long-term follow-up multicenter study from november 
2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 
2014. Data reflected that a platelet count ≤25 × 109/l at the time when the tpo-RA was initiated was 
associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on 
TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P < 0.001), and to 
previous splenectomy in younger patients (100% vs. 33%, P = 0.001). Receiving romiplostim as first 
TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 
years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas 
of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help 
clinicians make appropriate treatment decisions in the management of adult itp patients with tpo-RA.
Primary immune thrombocytopenia (ITP), is a rare acquired disease (ORPHA:3002) characterized by multiple 
alterations of the immune system leading to a significant reduction in the platelet number as a consequence of 
increased platelet destruction and impaired megakaryocytopoiesis1. The availability over the last decade of throm-
bopoietin receptor agonists (TPO-RA) for the treatment of ITP has transformed the management of this disease. 
Romiplostim, eltrombopag, and the recently FDA-licensed avatrombopag are TPO-RA that increase platelet 
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counts in ITP by activating the c-mpl receptor, promoting the survival, proliferation, and differentiation of mega-
karyocytes and subsequently stimulating platelet production. Although many physicians are well-acquainted with 
these agents, very few data exist related to certain decision-making determinations.
These drugs, specifically romiplostim and eltrombopag, are recommended second-line therapy for adult ITP 
patients in guidelines recently updated2,3. This recommendation is the result of systematic evidence validated by 
randomized, controlled trials with a placebo comparator4–6. Although the two TPO-RA may have similar overall 
efficacy, randomized clinical trials comparing both drugs have not been performed. For that reason, caution 
is needed due to heterogeneity between the study designs, patient populations, and response definitions when 
interpreting the results of indirect treatment comparisons; one metaanalysis supports equivalent efficacy and 
safety7, while others suggest that romiplostim may have greater efficacy8,9. Since it is not possible to draw definite 
conclusions based on current evidence, the choice of which TPO-RA to use seems to be an individual one, based 
on physicians and patients preferences.
Despite the fact that 60–90% of patients will respond to the initial TPO-RA10, some patients do not show 
that beneficial effect. In that case, given that these agents have different pharmacodynamic and pharmacokinetic 
properties, switching to the alternative TPO-RA may be a suitable approach11. In clinical practice, tapering off 
TPO-RA is contemplated to assess if this therapy is no longer needed due to a decrease in the disease activity 
favoring sustained treatment-free responses (TFR). These TFR, which have been observed in up to 10–30% of 
ITP patients receiving these drugs10, raise the question of additional potential immunomodulatory properties by 
increasing the regulatory T and B cell compartment and decreasing platelet destruction12,13. To date, there are no 
predictors to identify in which patients this approach is likely to be successful, other than earlier start of TPO-RA 
(which may relate to the pathophysiology of the disease), and robust platelet responses14–16.
These agents have been proven to be well-tolerated, and adverse events are usually mild. Some reports indi-
cate that TPO-RA have a potential for enhancing the inherent thrombotic risk of the disease (both venous and 
arterial). Although no properly designed trials have been conducted, the annualized thrombosis rates in adults 
with TPO-RA treatment appear to be 2–3 times higher than in an ITP population not treated with these agents17. 
Thromboembolic events appear to be more frequent in patients of older age and having at least 1 general risk 
factor for thrombosis, whereas it has no apparent relation to platelet count nor to the average or actual dose of 
either drug17. However, little information is available about different presentations of vascular events (VE) related 
to the TPO-RA being administered, or about the potential involvement of variables independent of traditional 
risk factors for thrombosis.
With the assumption that knowing additional post-authorization data about the use of TPO-RA can help 
to more strategically align the clinical practice and the management recommendations of patients with ITP, we 
undertook the present study aimed to (i) analyze practice patterns on the use of TPO-RA in “real-world” settings, 
with respect to indications, safety, switching, and TFR, and (ii) evaluate patients characteristics that might influ-
ence the selection of a particular TPO-RA over the other.
patients and Methods
Study design and selection criteria. This was an observational, retrospective, multicenter study con-
ducted in Spain from November 2016 to January 2018. The study was approved by the Clinical Research Ethics 
Committee of the Hospital General Universitario Morales Meseguer (Murcia, Spain) and the research project was 
carried out in accordance with the Declaration of Helsinki18. Written informed consent was obtained from every 
subject.
The participant investigators from 19 institutions with a wide geographic distribution had to recruit through 
the screening of the clinical records, all adult ITP patients who were alive and had started in their respective site 
TPO-RA from January 2012 to December 2014 as indefinite therapy. Patients were excluded if they had secondary 
ITP or if at the time they were prescribed the TPO-RAs they were participating in a clinical trial with investiga-
tional drugs.
The following information was obtained from the medical records: (1) demographics: age and sex; (2) 
diagnosis-related data: date of diagnosis, complete blood count (CBC), bleeding history, comorbidities, and diag-
nostic procedures performed; (3) previous therapies and responses; (4) TPO-RA administration: date and CBC 
at commencement, phase of the disease (newly diagnosed, persistent, or chronic ITP), bleeding, previous and 
concomitant treatment, indication for the TPO-RA, treatment duration, whether treatment with TPO-RA was 
switched and, if so, reason for switching, whether treatment with TPO-RA was discontinued by the time the 
information was recorded and, if so, reason for discontinuation, and achievement and duration of TFR. We con-
sidered TFR as platelet counts ≥50 × 109/l for at least 6 months in the absence of any therapies meant to increase 
platelet counts. Bleeding severity was evaluated at the time of diagnosis and also when TPO-RA was initiated, 
with an ITP bleeding score that includes the severity of bleeding at 11 specific sites, with scores ranging from 0 
to 2 (0 = none, 1 = mild, 2 = severe bleeding)19. Need for unscheduled hospital care requirements (emergency 
treatment or hospital admission) 6 months before and also 6 months after TPO-RA, and adverse events were 
also recorded. The final analysis was performed on data pooled from patients included from the 19 participating 
centers, with eleven institutions contributing three fourths of the total number of study participants.
Statistical analysis. A descriptive statistics analysis, including median, ranges, and percentages, was per-
formed. Differences in dichotomous variables were analyzed by Pearson’s χ2 test, and differences in continuous 
variables by the Mann-Whitney non-parametric test. Univariate logistic regression analyses were built in search 
of factors influencing odds ratios (OR) with 95% confidence interval (95% CI) of outcomes. Kaplan–Meier curves 
were built for TFR status within the study period. Results (given as percentages for categorical data, and median 
and range for continuous data) were considered statistically significant when the P‐value was less than 0.05. 
Statistical analysis was performed using SPSS software, version 23 (SPSS Inc., Chicago, IL).
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Results
A total of 121 patients (58.7% of them female) were enrolled in the study. In all cases patients were prescribed 
TPO-RA (romiplostim, n = 54; eltrombopag, n = 67) as indefinite therapy. The most frequent reasons for start-
ing long-term treatment with TPO-RA were refractoriness or loss of response (n = 76, 62.8%) and the need for 
continuous administration of other drugs (n = 31, 25.6%). Other causes were the need to increase platelet counts 
due to antiplatelet or anticoagulant therapy (n = 4, 3.3%), or the wish to delay splenectomy (n = 9, 7.4%). Baseline 
characteristics of the study cohort are presented in Table 1. When TPO-RA were initiated, the majority of cases 
(67.8%) were chronic ITP (median time from diagnosis 65.6 months; 12.7 to 603.4 months), while 15.7% of 
patients had persistent and 16.5% newly diagnosed disease. The median initial doses of the eltrombopag were 
350 mg/week (150–525 mg/week), and 2 μg/kg/week (1–7 μg/kg/week) in the case of romiplostim. To capture 
enough events to reveal meaningful patterns, a long-term follow-up study was designed. The median time from 
start of TPO-RA until collection of data was of 44.9 months (23.8 to 67.5 months), whereas that under TPO-RA 
treatment was 35.2 months (1 to 67.3 months). Although the initial intention to treat was indefinite therapy, at last 
follow-up only 65 patients (53.7%) continued to receive treatment with TPO-RA. There was a trend towards using 
eltrombopag in older patients (median 66 years; 21–96 years, romiplostim median age 57 years; 19–90 years; 
P = 0.115), and with more comorbid conditions, although differences were not statistically significant except for 
hypertension (Table 1). Neither gender, liver disease, phase of the disease, previous history of neoplasia or VE, 
nor exposure or responses to previous lines of therapy were associated with the choice of TPO-RA (P > 0.05) 
(Table 1).
We assessed whether the prescription of a particular TPO-RA could be related with the risk of bleeding19. 
At diagnosis of the disease, bleeding symptoms were more frequent and more severe among patients that were 
subsequently treated with romiplostim than with eltrombopag (66.7% vs. 41.8% of bleeders, P = 0.006; median 
cumulative bleeding score of 2 vs. 0, P = 0.003). At the time when TPO-RA was initiated, bleeding manifestations 
and platelet counts were also correlated with the selection of TPO-RA; the median cumulative bleeding score 
was of 1 vs. 0, P = 0.037, and the median platelet counts of 18 × 109/l vs. 25 × 109/l, P = 0.014, in romiplostim and 
eltrombopag treated patients, respectively. Additionally, six months before the start of TPO-RA, the requirement 
for hospital care (emergency treatment or hospital admission) was higher in patients that would later on receive 
romiplostim than in those elected for eltrombopag (55.6% vs. 31.8%, P = 0.009) (Table 2). Among the 74 episodes 
of unscheduled hospital visits, 75.7% of the cases were related to bleeding, and 12.2% to infection. In 62.2% of 
the episodes where patients presented at the hospital, they were discharged following management in the emer-
gency department (in 83.9% due to hemorrhagic symptoms), and non-bleeding causes accounted for 35.7% of 
the admissions to hospitals.
Safety. thrombotic events. We examined whether the initiation of TPO-RA had an impact on the patient 






(N = 67) P
Gender (% Female) 58.7 59.3 58.2 0.907
Platelets at diagnosis (median, range) 11.5, 0–95 12, 1–82 11, 0–95 0.899
Age (median, range) 63, 19–96 57, 19–90 66, 21–96 0.115
Hypertension (%) 28.1 16.7 37.3 0.012
Diabetes (%) 14.0 11.1 16.4 0.404
Liver disease (%) 4.1 3.7 4.5 0.832
Previous neoplasia (%) 6.6 5.5 8.1 0.675
Previous vascular event (%) 9.1 7.4 7.2 0.563
Chronic phase (%) 67.8 68.5 67.2 0.874
Patients that started TPO-RA in the first 18 
months (January 2012–June 2013) (%) 48.8 53.7 44.8 0.329
Previous therapies






































































Table 1. Patients’ characteristics and previous therapies. Immunosuppresants include azathioprine, 
cyclophosphamide, or cyclosporine.
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in the percentage of patients, and in the number of times these patients required emergency treatment or hos-
pital admission in the 6 months following- compared to the 6 months before- TPO-RA therapy (20.2% vs. 42%, 
P = 0.007; 37 vs. 74 episodes, P = 0.031).
The tolerance of the agents was generally very good; adverse events were usually mild, most frequently causing 
myalgia, arthralgia, headache, or abdominal discomfort, and reported at equally low rates (<10%) in patients 
with either eltrombopag or romiplostim. One patient receiving romiplostim was diagnosed with a solid tumor, 
and in two cases a significant increase in liver enzymes was reported with eltrombopag. Nine individuals in each 
group underwent bone marrow assessment following TPO-RA, and bone marrow fibrosis was reported in two 
patients under romiplostim therapy. In one patient bone marrow examination was not repeated, whereas in the 
other, one year after romiplostim was stopped a regression of myelofibrosis from from MF-3 to MF-1 was con-
firmed. The assessment of the rate of VE during the interval under treatment of 329.3 patient-year revealed 15 
patients experiencing 17 VE. These included 9 thrombotic events (6 pulmonary embolism, 3 venous thrombo-
sis), and 8 ischemic episodes (3 stroke, 2 transient ischemic attack, 1 angina pectoris, 1 myocardial infarction, 1 
peripheral ischemic event). TPO-RA were continued during the acute event in 10 cases, and later resumed in 4 
additional episodes where patients were transitorily switched to a different ITP therapy. In the course of venous 
thrombosis, anticoagulation was always initiated, and antiplatelet therapy was started in all patients presenting 
with ischemia. In all cases but one (sequela of mild dysarthria), the clinical recovery from the VE was complete.
Before TPO-RA, 11 of the 121 included patients had presented VE; nonetheless TPO-RA did not seem to 
predispose to new events, since such history of prior thromboembolic or ischemic events was present only in 
one of the 15 patients with VE during TPO-RA therapy. The median platelet count when the VE under TPO-RA 
occurred was 110 × 109/l (10–648 × 109/l). Ten out of the 15 patients continued TPO-RA at last follow-up. 
Seven events occurred with romiplostim, and 10 with eltrombopag. The annualized risk was 4.2 and 5.9 VE/100 
patient-years in romiplostim and eltrombopag treated patients, respectively (median 5.2). The calculated inci-
dence therefore was of one VE for every 17 patient-year receiving eltrombopag, and one VE event for every 23 
patient-year receiving romiplostim. Most VE occurred in the first year of TPO-RA therapy (median 276 days; 
range 5–1183), with a trend toward earlier events under romiplostim than eltrombopag (127 days vs. 360 days, 
respectively; P = 0.070). In the case of ischemic events the median time to arterial events was 165 vs. 606 days in 
romiplostim and eltrombopag treated patients; P = 0.029.
The comorbidities of patients that subsequently developed VE included one patient presenting with antiphos-
pholipid antibodies, five having been diagnosed with neoplasia, one with vascular peripheral disease, and two 
with hypothyroidism –one of whom also had renal disease. When the TPO-RA was started, all patients were 
reported to have sustained complete remission of previous neoplasias (1 colon carcinoma; 1 Burkitt lymphoma; 
1 bladder cancer; 1 breast cancer; 1 patient with history of thyroid, breast and ovarian tumors) and none of them 
was receiving any cancer-specific therapies. There were no significant differences in the 15 patients vs. the 106 
patients that did not suffer from VE in terms of gender, age, diabetes, hypertension, previous vascular events, or 
time on prednisone as 1st line therapy. Factors associated with the occurrence of a VE were previous splenectomy 
(53.3% vs. 25.5%, P = 0.026), chronic phase of the disease (93.3% vs. 64.1%, P = 0.024), and a personal history 
of malignancy (33.0% vs. 2.8%, P < 0.001). Table 3 shows the results of the univariate logistic regression model. 
Splenectomy and previous malignancy were found to be significant factors related to thrombotic events. However, 
when patients were dichotomized according to age, just in those over 65 years experiencing VE on TPO-RA 
(8 out of 54) a history of previous neoplasia was associated with VE (50% vs. 2.2%, P < 0.001), whereas only in 
younger patients with VE during TPO-RA therapy (7 out of 67), previous splenectomy was related to those inci-
dents (100% vs. 33%, P = 0.001).
OR 95% CI P
Bleeding at diagnosis 2.7 1.29–5.73 0.009
Bleeding score at diagnosis >2 2.9 1.25–6.57 0.013
Bleeding score when TPO-RA was started >1 2.5 1.18–5.46 0.017
Platelet count when TPO-RA was started ≤25 × 109/l 2.8 1.27–6.04 0.010
Need for unscheduled hospital care in the previous 6 months 2.7 1.27–5.74 0.010
Table 2. Univariate logistic regression model for factors related to bleeding risk potentially affecting the 
selection of a particular TPO-RA. OR indicates the probability of choosing romiplostim over eltrombopag. 
Abbreviations: TPO-RA, thrombopoietin receptor agonist.
OR 95% CI P
Univariate analysis
Splenectomy 3.3 1.11–10.09 0.032
Chronic disease 7.8 0.99–61.83 0.051
Previous malignancy 17.2 3.57–82.65 <0.001
Table 3. Univariate logistic regression model for factors related to vascular events during TPO-RA therapy. OR 
indicates the probability of having a vascular event under TPO-RA therapy in the presence of a specific factor. 
Abbreviations: TPO-RA, thrombopoietin receptor agonist.
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Switching and discontinuation. therapy free responses. Although initially more patients received 
eltrombopag than romiplostim as chronic therapies (n = 67 vs. n = 54, respectively), due to switching, the 
exposure to both TPO-RAs was similar: 80 patients received romiplostim for a total exposure of 161.0 years, 
and also 80 individuals were treated with eltrombopag for total exposure of 168.3 years. Overall, 39 patients 
(32.2%) switched TPO-RA, with a trend towards more common drug exchange in eltrombopag-treated patients 
(38.8% of those that initiated this TPO-RA) than among romiplostim-treated patients (24.1% of patients that 
initially received this agent) (P = 0.085). The rates of TPO-RA switching were not significantly different between 
chronic ITP patients and those with non-chronic phases (35.4% vs. 25.6%, respectively; P = 0.285). The rea-
sons for switching differed between the initial TPO-RA being administered; efficacy issues were more frequent 
among patients treated with eltrombopag (17 out of the 26 patients that switched eltrombopag vs. 2 out of 13 that 
switched romiplostim; P = 0.003), while patients’ or doctors’ preference was a more common cause to substitute 
romiplostim (8 patients) than eltrombopag (2 patients), P < 0.001. Other reasons for switching included adverse 
events (5 patients with eltrombopag), platelet fluctuation (2 cases with romiplostim), or perioperative surgical 
procedures (1 with romiplostim, and 2 with eltrombopag).
From the start of TPO-RA until data collection almost one half of the patients (46.3%, n = 56) tapered-off 
TPO-RA. Patients that discontinued TPO-RA non due to lack of response and with a follow-up longer than 6 
months (n = 41), were followed for 27.1 months (9.2–55.0) in the case of romiplostim (n = 23), 28.1 months (7.0–
44.8) for those that stopped eltrombopag (n = 12), 20.7 months (10.1–31.2) for patients tapering off romiplostim 
having previously received eltrombopag (n = 2), and 31.5 months (24.1–56.4) for those ceasing eltrombopag 
having switched from romiplostim (n = 4). The Kaplan Meier curve of relapse-free remission of these 41 patients 
is displayed in Fig. 1. A total of 35 patients (85.4% of those that stopped TPO-RA) achieved TFR after a median 
time under TPO-RA treatment of 14.2 months. Romiplostim was discontinued in 21 cases, eltrombopag in 10 
cases, and in 4 cases patients received both TPO-RA due to switching. In 4 of these 35 patients (3 patients having 
received romiplostim, and 1 having switched TPO-RA), these agents were reintroduced due to loss of response 
after a median TFR period of 20.5 months.
Potential predictors of TFR in the remaining 31 patients (25.6%) that sustained platelet counts for a median 
of 32 months (8–217 months) were analyzed. No specific patient features (e.g. age, comorbidities, ITP duration, 
previous treatments, bleeding, nor phase of disease) seemed to consistently predict for TFR (P > 0.05). However, 
statistically significant predictors of TFR were identified: interestingly, while the specific TPO-RA that was dis-
continued did not influence the probability to achieve TFR, romiplostim as first TPO-RA was positively associ-
ated (3.0 increased probability) with TFR (P = 0.011), while switching TPO-RA was associated with a 8.8 risk of 
not achieving TFR (P = 0.004) (Table 4).
Although there was a significant difference in the initial response to the first TPO-RA (7% vs. 25% of 
non-responders to romiplostim and eltrombopag, respectively; P = 0.009), however, other additional factors to 
platelet responses should be involved in the different TFR between TPO-RA. Data revealed that in patients that 
received only romiplostim (n = 41), or solely eltrombopag (n = 41), the rate of responses were similar (95.1% 
responders in both groups not exposed to switching). In contrast, the probability of attaining TFR in patients that 
received only romiplostim was 3.2 higher than those exposed only to eltrombopag (P = 0.014).
Figure 1. Probability of maintaining therapy free responses (TFR) upon TPO-RA discontinuation. Kaplan-
Meier plot showing the estimated probability of TFR in patients who discontinue TPO-RA for reasons 
other than lack of efficacy and being followed for a minimum of 6 months (n = 41). Patients who died while 
on TPO-RA therapy were not included in the study. Solid black line represents patients that received only 
romiplostim (n = 23); solid grey line represents patients that received only eltrombopag (n = 12), and dashed 
black line represents patients that switched TPO-RA (n = 6). The number of patients that discontinue TPO 
therapy (“at risk”) and the cumulative loss of TFR events at time points are presented for each group below the 
figure.
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Of the 41 patients that were treated with romiplostim (median time 26.1 months; 1.0–67.3), 21 of them 
(51.3%) achieved TFR. When considering the 41 patients treated with eltrombopag (median time on TPO-RA 
of 38.6 months; 1.5–63.8), ten of them (24.4%) were able to discontinue the drug successfully. The percentage 
of patients that maintained TFR after tapering off TPO-RA was 15.4% of those switching from romiplostim to 
eltrombopag, and 7.7% of those that alternated from eltrombopag to romiplostim (median duration of TPO-RA 
therapy of 44.2 months; 4.4–61.6, and 34.1 months; 2.4–61.4, respectively).
To minimize the confounding variable of mistakenly attributing TPO-RA induced TFR, when in fact it could 
be a consequence of the natural course of the underlying disease, we analyzed the subset of 82 patients with 
chronic ITP (median time from diagnosis of ITP to therapy with TPO-RA of 5.5 years; 1.1–50.3 years). In this 
group of patients, there was a trend towards receiving romiplostim as first TPO-RA and attaining sustained 
responses (P = 0.073), while switching TPO-RA was significantly associated with a 6.4 risk of not achieving TFR 
(P = 0.019). In chronic ITP patients, TFR were achieved in 44.8% of patients after romiplostim discontinuation, 
and in 25% following tapering off eltrombopag; TFR were observed in 12.5% among those that alternated from 
romiplostim to eltrombopag, and in 4.7% of patients switching from eltrombopag to romiplostim.
Data reflected that patients receiving romiplostim and not experiencing switching were the best performing 
group in terms of achieving TFR. Thus, in the whole cohort, 50% of patients tapered off the drug after a median 
of 2.9 yrs (95% CI 1.7–4.2 years) and sustained TFR (Fig. 2a), while the same behavior was seen in chronic ITP 
patients after a median of 3.3 years (95% CI 2.7–4.0 years) (Fig. 2b).
Discussion
Eltrombopag and romiplostim are effective drugs that have been established as a mainstay in the treatment 
of patients with ITP providing an excellent long-term outlook. Response rates from clinical trials7–9 and clin-
ical practice data20 do not seem to differ greatly between both agents, though none of the studies provided a 
randomized comparison. Thus, the choice between eltrombopag and romiplostim is a matter of availability, 
OR 95% CI P
Romiplostim as first 
TPO-RA 3.0 1.28–7.01 0.011
No switching 8.8 1.97–39.26 0.004
Table 4. Univariate logistic regression model for factors related to therapy free responses. OR indicates 
the probability of therapy free responses associated to the factor indicated. Abbreviations: TPO-RA, 
thrombopoietin receptor agonist.
Figure 2. Percentages of patients that achieve therapy free responses (TFR). Proportion of patients achieving 
TFR within the whole cohort (n = 121) included in the study (panel a), and in those with chronic ITP (panel 
b). TFR was defined as the ability of a patient to discontinue TPO-RA and sustain platelet counts >50 × 109/l 
for at least 6 months in the absence of any therapies meant to increase platelet counts. Patients who died while 
on TPO-RA therapy were not included in the study. Solid black line represents patients that received only 
romiplostim (Panel a, n = 41; Panel b, n = 29). Solid grey line represents patients that received only eltrombopag 
(Panel a, n = 41; Panel b, n = 24). Dashed black line represents patients that initiated romiplostim and switched 
to eltrombopag (Panel a, n = 13; Panel b, n = 8). Dashed grey line represents patients that initiated eltrombopag 
and switched to romiplostim (Panel a, n = 26; Panel b, n = 21). The number of patients under TPO therapy (“at 
risk”) and the cumulative TFR at time points are presented for each group below each figure.
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convenience and cost. Our observational data indicate that in real world setting, the choice of one TPO-RA over 
the other for long-term treatment of ITP could be conditioned by attributes other than the mode of administra-
tion of these drugs and/or patient’s preference. We found that lower platelet counts and hemorrhagic symptoms 
relate to a higher likelihood of prescribing romiplostim over eltrombopag. This suggests that the prescription 
of the TPO-RA could be related to some extent with the risk of bleeding before initiating treatment. In these 
situations, romiplostim is given preferentially to patients, probably based on the wider dosage range of the drug 
that may allow earlier responses with higher doses, as suggested in a small sample size study21. Additionally, the 
subcutaneous administration avoids potential dietary interferences, and adherence to treatment is secured. In 
agreement with our clinical practice data, a recent network analysis indicates that romiplostim may rank slightly 
higher than eltrombopag for the probability of achieving early responses9. However, due to the limitations of the 
few randomized clinical trials that were included, inaccurate assumptions should not be made until reliable data 
demonstrate distinct response patterns with different TPO-RA.
Similar to the above mentioned paucity information related to time to platelet responses, data about dif-
ferences in the overall platelet responses with these agents is also scarce, with some studies reporting similar 
outcomes7, and others indicating that romiplostim produces better results8,9. In our cohort of patients, lack of 
response as reason for switching TPO-RA was more frequent among eltrombopag-treated patients (25.4% vs. 
3.7% of those initially treated with each drug). These results differ from more than 250 reported cases that have 
been switched from one TPO-RA to another11. The analysis of patients included in 12 studies reflects that in 
total 67/103 (eltrombopag to romiplostim) and 76/165 (romiplostim to eltrombopag) switched for non-efficacy 
issues22,23. The incongruence of the current and previous data may be based on (i) the heterogeneity in manage-
ment of patients receiving or not maximum product dose as per prescribing information (eltrombopag 75 mg/
day, or romiplostim 10 μg/kg, in both cases for 4 weeks) prior to TPO-RA switching, which may influence effi-
cacy, and (ii) previous reports do not express data as percentage of patients that alternate among those that start a 
specific TPO-RA, so that results cannot be directly compared.
In general, the tolerability of these drugs was very good, and adverse events were not a major reason for switch-
ing or for discontinuation. In fact, these therapies were associated with decreased healthcare resource utilization 
defined as hospital admission or emergency department visits. Similar to other reports17,24, TPO-RA however 
seemed to increase the incidence of thrombosis, with an annualized risk of 5.2 VE/100 patient-years in TPO-RA 
treated patients. Interestingly, we found that the history of curable malignancy was a strong factor associated 
with the occurrence of thromboembolic or ischemic events in elderly ITP patients. It is well-known that active 
cancer is associated with a 4- to 7-fold increased risk of venous thromboembolism compared with non-cancer 
patients25,26, probably due to factors related to cancer per se (e.g. a hypercoagulable state, or treatment-related 
effects)27. Limited data suggest that these mechanisms resulting in an increased risk of VE in cancer may persist 
even after the cancer is in remission28. In line with that, in ITP patients, a past history of malignancy increases 
the risk of venous thromboembolism with an HR of of 1.829. However, in our study the risk of VE in ITP patients 
with a history of previous neoplasia while on TPO-RA was disproportional (more than 40-fold increased risk in 
elderly patients), suggesting a novel association of these variables with VE in elderly ITP patients under TPO-RA 
therapy. Our data indicate that however, at younger ages, splenectomy is the strongest factor influencing the like-
lihood to suffer from these events. Although further research is warranted, these data highlight the relevance of 
the evaluation of age and comorbidities before initiation of TPO-RA, including the history of malignancies and 
splenectomy, when managing the care of these patients.
In the last years there has been progress in our knowledge of potential TFR in a number of patients treated 
with TPO-RA, and such data from the published series, together with the good efficacy/safety profile have posi-
tioned these drugs as one of the second-line treatments of choice today, as confirmed by recent guidelines2,3. 
Information is still sparse regarding prognostic factors and their implications for treatment. In particular, we 
designed a study with long-term assessment of outcomes with TPO-RA, to better enable the evaluation of out-
comes of therapies with these agents. Additionally, we aimed to assess clinical predictors of TFR by dealing with 
confounding variables, specifically minimizing the possible bias of attributing TPO-RA induced TFR, when in 
fact it may be the natural course of disease, by analyzing a group of chronic ITP patients with a particularly poor 
baseline prognosis (median time from diagnosis 5.5 years).
In this long-term follow-up analysis, we confirm that platelet responses following TPO-RA cessation is sus-
tained in 25.6% of adult patients with primary ITP, and identified variables that in real life seem to predict signif-
icantly higher odds of TFR. While in our study the specific TPO-RA that was discontinued did not influence the 
probability to achieve TFR, receiving romiplostim as first TPO-RA was positively associated with a 3-fold greater 
likelihood of achieving TFR, while switching TPO-RA negatively predicted sustained platelet responses. The fact 
that the percentage of responders was similar in patients that received only a single type of TPO-RA indicates 
that factors other than platelet responses may be involved in the increased TFR observed in romiplostim treated 
individuals. Whether this is due to the recently proposed hypothesis of tolerogenic properties of romiplostim, 
attributed to the “carrying” Fc molecule30 or to additional factors, is still an unanswered question to be unveiled.
Receiving romiplostim as first TPO-RA and avoiding its switching associates with a 50% likelihood of TFR 
after 2.9 years of therapy. These data did not differ substantially from those of chronic ITP patients, where assur-
ing that long duration under TPO-RA therapy was provided (median of 3.3 years), one half of chronic ITP 
patients treated with romiplostim and not undergoing switching also achieved TFR.
The main limitation of our study is its observational retrospective design, although it could also represent 
a strength, since it encompasses heterogeneous patients in the clinical practice managed by different doctors 
in distinct institutions. From these data we conclude that in clinical practice, TPO-RAs are frequently used as 
second-line therapies, regardless of the chronicity of the disease. In this context, there seems to be a preferential 
use of romiplostim for patients with increased bleeding risk, which also appears to associate with higher TFR, 
while both TPO-RA exhibit a similar tolerability and safety profile. However, we acknowledge that results of our 
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study are difficult to put into perspective with previous observational studies because of differences in popula-
tions, follow-up and outcomes. For that reason, a long-term pragmatic randomized clinical trial would be desira-
ble to overcome some the above-mentioned limitations and to corroborate these findings.
conclusion
This retrospective multicenter study with long-term follow-up offers insight into some of the most relevant 
real-world challenges in the treatment of ITP patients with TPO-RA. Data reflect that in clinical practice, the 
patient’s hemorrhagic risk determines the choice TPO-RA, and distinguishes novel variables associated with vas-
cular events under therapies with thrombopoietic agents. Additionally, we confirm that more than one-fourth of 
patients can discontinue these agents and sustain TFR, and identify predictive clinical markers that indicate that 
one half of specifically managed subsets of ITP patients can achieve these TFR.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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